Sugi Predict

Sugi Predict / Compounds / SCHEMBL5694191

SCHEMBL5694191

SCHEMBL5694191

Nc1nc2nc[nH]c2c(=O)n1C(=O)c1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 4/20 0.51
▸ RAB9A P51151 4/20 0.51
▸ SMN1; SMN2 Q16637 3/20 0.51
▸ MEN1 O00255 1/20 0.51
▸ KMT2A Q03164 1/20 0.51
▸ KDM4E B2RXH2 2/20 0.44
▸ PKM P14618 1/20 0.44
▸ CDK2 P24941 3/20 0.42
▸ CDK1 P06493 2/20 0.42
▸ CCNB1 P14635 2/20 0.42
▸ MGMT P16455 2/20 0.42
▸ CCNA2 P20248 2/20 0.42
▸ CCNA1 P78396 2/20 0.42
▸ LMNA P02545 3/20 0.41
▸ POLB P06746 1/20 0.41
▸ NOD1 Q9Y239 1/20 0.41
▸ BRD4 O60885 1/20 0.40
▸ CYP1A2 P05177 3/20 0.40
▸ PNP P00491 2/20 0.40
▸ ADORA3 P0DMS8 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29131185 0.84 CDK2 (0.38) NPC1RAB9ASMN1; SMN2MEN1KMT2A
Benzene SCHEMBL8024450 0.82 MGMT (0.43) CDK2CDK1CCNB1MGMTCCNA2
SCHEMBL28368763 0.81 PNP (0.45) MEN1KMT2AKDM4ECDK2CDK1
SCHEMBL1740468 0.81 PNP (0.40) CDK2CDK1CCNB1MGMTCCNA2
SCHEMBL6821773 0.80 PNP (0.45) CDK2MGMTLMNACYP1A2PNP
SCHEMBL25398225 0.79 LMNA (0.53) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL5694108 0.79 MEN1 (0.41) MEN1KMT2AKDM4ECDK2CDK1
SCHEMBL218669 0.79 MGMT (0.45) CDK2CDK1CCNB1MGMTCCNA2
SCHEMBL5694185 0.79 NPC1 (0.51) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL6267430 0.79 PNP (0.45) NPC1RAB9ASMN1; SMN2KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117924393-A Monomer of 3' -mercapto nucleoside analogue and its synthesis process 天津兴博润生物制药有限公司 2024-04-26 — — CN claimed
CN-106117289-B 2 '-O-MOE-3 '-H- thiophosphate nucleoside monomers and its synthetic method 郑州大学 2019-02-12 — — CN claimed
CN-106117289-A 2 ' O MOE 3 ' H thiophosphate nucleoside monomers and synthetic methods thereof 郑州大学 2016-11-16 — — CN claimed
WO-1992011276-A1 NOVEL SYNTHESIS OF 2'-'UP' FLUORINATED 2''-DEOXY-ARABINOFURANOSYLPURINES SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 1992-07-09 — — WO claimed
JP-58198500-A — — None — — JP disclosed
US-20240150391-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF MAKING THE SAME GERON CORP (US) 2024-05-09 — — US disclosed
CN-117924393-A Monomer of 3' -mercapto nucleoside analogue and its synthesis process 天津兴博润生物制药有限公司 2024-04-26 — — CN disclosed
CN-117412753-A Bruton's tyrosine kinase inhibitors and methods of use thereof 詹森药业有限公司 2024-01-16 — — CN disclosed
CN-117357548-A Oligonucleotide composition and method for preparing same 美国杰龙生物医药公司 2024-01-09 — — CN disclosed
EP-4286519-A2 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF MAKING THE SAME GERON CORPORATION (US) 2023-12-06 — — EP disclosed
CN-111228288-B Oligonucleotide composition and method for preparing same 美国杰龙生物医药公司 2023-10-20 — — CN disclosed
EP-3137479-B1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF MAKING THE SAME GERON CORP (US) 2023-08-30 — — EP disclosed
EP-0882059-B1 SOLID PHASE SYNTHESIS OF OLIGONUCLEOTIDE N3-'P5'- PHOSPHORAMIDATES LYNX THERAPEUTICS INC (US) 2002-02-06 — — EP disclosed
CN-1068308-C Substituted benzoylguanide preparation and pharmaceutical application of same HOECHST AG (DE) 2001-07-11 — — CN disclosed
CN-1057760-C Amino acid-substituted benzoylguanidines, a process for their preparation, their use as a medicament or diagnostic agent and a medicament containing them HOECHST AG (DE) 2000-10-25 — — CN disclosed
CN-1127749-A Amino acid-substituted benzoylguanidines, a process for their preparation, their use as a medicament or diagnostic agent and a medicament containing them HOECHST AG (DE) 1996-07-31 — — CN disclosed
EP-0700899-A1 Substituted benzoylguanidines, a process for their preparation, their use as drug or diagnostic agents as well as medicaments containing them HOECHST AKTIENGESELLSCHAFT (DE) 1996-03-13 — — EP disclosed
WO-1992011276-A1 NOVEL SYNTHESIS OF 2'-'UP' FLUORINATED 2''-DEOXY-ARABINOFURANOSYLPURINES SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 1992-07-09 — — WO disclosed
EP-0105486-A2 1-Monophosphate esters, 1,3-bisphosphate esters and cyclic phosphate esters of 9-(1,3-dihydroxy-2-propoxymethyl)-guanine as antiviral agents SYNTEX (U.S.A.) INC. (US) 1984-04-18 — — EP disclosed
JP-S58198500-A RIBONUCLEOSIDE SUBSTITUTED WITH 4-METHOXYBENZYL GROUP IN THE 2'-POSITION MITSUI TOATSU CHEM INC 1983-11-18 — — JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240150391-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF MAKING THE SAME RNGTT, NSUN2, POLN NPC1 4296/4885RAB9A 4873/4885SMN1; SMN2 589/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.